Corvus Pharmaceuticals, Inc. — Director's Dealing 2025

Apr 9, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Corvus Pharmaceuticals, Inc. (CRVS)
CIK: 0001626971
Period of Report: 2025-04-08

Reporting Person: van den Broek Richard (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-04-08	Stock Option (Right to Buy)	$2.82	A	30000	Acquired	2035-04-08	Common Stock (30000)	Direct

Footnotes

F1: The underlying shares subject to the option vest and become exercisable as to one-third (1/3rd) of the shares subject to the option on each annual anniversary measured from April 8, 2025, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.